BIOMAT Database Logo BIOMAT Database Logo

Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors. 1993

A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Department of Medicinal Chemistry, Molecular Biology, and Virus and Cell Biology, Merck Research Laboratories, West Point, Pennsylvania 19486.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D006571 Heterocyclic Compounds Cyclic compounds that include atoms other than carbon in their ring structure. Heterocyclic Compound,Compound, Heterocyclic,Compounds, Heterocyclic
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013450 Sulfones Sulfone
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
SYNTHESIS AND OPTICAL RESOLUTION OF HIGH AFFINITY P2-LIGANDS FOR HIV-1 PROTEASE INHIBITORS.
January 1995, Tetrahedron letters,
A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.
February 2010, Bioorganic & medicinal chemistry letters,
A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
November 1999, Bioorganic & medicinal chemistry letters,
A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
March 1998, Bioorganic & medicinal chemistry letters,
A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
June 2011, Bioorganic & medicinal chemistry letters,
A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
April 2006, Bioorganic & medicinal chemistry letters,
A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
May 2015, Bioorganic & medicinal chemistry letters,
A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors.
November 2008, Organic letters,
A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
April 1998, Bioorganic & medicinal chemistry letters,
A K Ghosh, and W J Thompson, and H Y Lee, and S P McKee, and P M Munson, and T T Duong, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
October 2008, Journal of medicinal chemistry,
Copied contents to your clipboard!